文献速递脑血管病

心房颤动相关急性缺血性卒中结局的时代趋势及新型口服抗凝药的影响

Secular Trends in Outcomes and Impact of Novel Oral Anticoagulants in Atrial Fibrillation-Related Acute Ischemic Stroke.
PubMed 文献 · Stroke · 2024-02-08

该多中心卒中登记研究纳入2011年1月至2019年12月的12 500例房颤相关急性缺血性卒中患者,评估新型口服抗凝药(NOAC)处方率与临床事件年度趋势。主要复合结局1年发生率从2011年28.3%降至2019年21.7%,NOAC处方率从0%升至75.6%,中介分析提示NOAC处方介导了日历年份与主要结局之间的关联。

要点

  • 主要复合结局1年发生率从2011年28.3%降至2019年21.7%。
  • NOAC处方率从2011年0%升至2019年75.6%。
  • 控制NOAC处方后,日历年份对主要结局的影响不再显著(校正时间比0.97,95%CI 0.94-1.00)。

核心结论

  • 韩国房颤相关急性缺血性卒中患者主要临床事件或死亡随时间下降,该趋势由NOAC处方增加所介导,强调该人群使用NOAC。

研究设计与样本

  • 多中心卒中登记研究,纳入2011年1月至2019年12月房颤相关急性缺血性卒中患者,排除瓣膜性房颤后分析12 500例(平均年龄74.4岁,51.3%男性)。
  • 评估NOAC年度处方率及1年内临床事件,采用自然效应模型及多变量回归或加速失效时间模型进行中介分析,并校正潜在混杂因素。

主要发现

  • 主要复合结局(复发性卒中、心肌梗死和全因死亡)1年发生率从2011年28.3%降至2019年21.7%。
  • 日历年份每增加1年与主要结局发生延迟独立相关(校正时间比1.10,95%CI 1.07-1.14),并与NOAC处方增加相关(校正比值比2.20,95%CI 2.14-2.27)。
  • NOAC处方增加与主要结局发生延迟相关(校正时间比3.82,95%CI 3.17-4.61)。
  • 控制NOAC处方(中介变量)后,日历年份不再影响主要结局(校正时间比0.97,95%CI 0.94-1.00)。

临床怎么用

  • 原文结论强调房颤相关急性缺血性卒中人群使用NOAC。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Novel oral anticoagulants (NOACs) are currently recommended for the secondary prevention of stroke in patients with acute ischemic stroke (AIS) accompanied by atrial fibrillation (AF). However, the impact of NOACs on clinical outcomes in real-world practice remains ambiguous. This study analyzes the trend of clinical events in patients with AF-related AIS and determines how much the introduction of NOACs has mediated this trend. METHODS: We identified patients with AIS and AF between January 2011 and December 2019 using a multicenter stroke registry. Annual rates of NOAC prescriptions and clinical events within 1 year were evaluated. The primary outcome was a composite of recurrent stroke, myocardial infarction, and all-cause mortality. To assess the mediation effect of NOACs on the relationship between the calendar year and these outcomes, we used natural effect models and conducted exposure-mediator, exposure-outcome, and mediator-outcome analyses using multivariable regression models or accelerated failure time models, adjusting for potential confounders. RESULTS: Among the 12 977 patients with AF-related AIS, 12 500 (average age: 74.4 years; 51.3% male) were analyzed after excluding cases of valvular AF. Between 2011 and 2019, there was a significant decrease in the 1-year incidence of the primary composite outcome from 28.3% to 21.7%, while the NOAC prescription rate increased from 0% to 75.6%. A 1-year increase in the calendar year was independently associated with delayed occurrence of the primary outcome (adjusted time ratio, 1.10 [95% CI, 1.07-1.14]) and increased NOAC prescription (adjusted odds ratio, 2.20 [95% CI, 2.14-2.27]). Increased NOAC prescription was associated with delayed occurrence of the primary outcome (adjusted time ratio, 3.82 [95% CI, 3.17 to 4.61]). Upon controlling for NOAC prescription (mediator), the calendar year no longer influenced the primary outcome (adjusted time ratio, 0.97 [95% CI, 0.94-1.00]). This suggests that NOAC prescription mediates the association between the calendar year and the primary outcome. CONCLUSIONS: Our study highlights a temporal reduction in major clinical events or death in Korean patients with AF-related AIS, mediated by increased NOAC prescription, emphasizing NOAC use in this population.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Lee M, Lee BC, Yu KH, et al. Secular Trends in Outcomes and Impact of Novel Oral Anticoagulants in Atrial Fibrillation-Related Acute Ischemic Stroke. Stroke. 2024. PMID: 38328909. doi:10.1161/STROKEAHA.123.044487

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。